Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HUBPE006.1
- Development stage
- Preclinical
- Lead developer
- Ambiotech
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
HUBPE006.1 is an exosome-based therapy developed by AM Biotech using its proprietary Biochemical Pulse Exosome Drug Development Platform. It is currently in preclinical development for the treatment of degenerative arthritis and as a bone medical device. The therapy utilizes exosomes to deliver therapeutic signals or components to target tissues, aiming to regenerate or repair bone and joint structures. In the context of orthopedic indications, it is being developed within a medical device regulatory framework. The Biochemical Pulse platform is designed to enhance the therapeutic potential of exosomes for various regenerative medicine applications.
Beyond the preview
Go deeper on HUBPE006.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUBPE006.1.